Disc Medicine (IRON) COO Yu Jonathan Yen-Wen Sells 9,700 Shares

Yu Jonathan Yen-Wen, the Chief Operating Officer of Disc Medicine, Inc., sold 9,700 shares of the company on June 22, 2026. This transaction reflects insider activity at the biotech firm, which trades on the NasdaqGM under the ticker IRON.

Insider Buying and Selling at Disc Medicine, Inc.

Yu Jonathan Yen-Wen, the company's COO, engaged in several transactions on June 22, 2026. He sold 9,700 shares, while also acquiring the same number of shares at an average price of $13.50 in a separate transaction. Additionally, Rahul Khara, the Chief Legal Officer, purchased 7,500 shares on June 18, 2026, at an average price of $14.69.

Other Institutional Activity in Disc Medicine

FMR LLC increased its holdings in Disc Medicine by 136,672 shares, bringing its total to about 5.59 million shares, valued at approximately $357.23 million. RA Capital Management added 474,089 shares, resulting in a 24% increase to 2.45 million shares worth $156.67 million. Wellington Management grew its position by 217,102 shares, a 14.3% increase, now holding 1.74 million shares valued at $110.96 million. Meanwhile, BlackRock slightly reduced its stake by 1,149 shares, maintaining a total of 2.27 million shares worth $145.39 million.

Disc Medicine, Inc. Stock Up 1.2%

On Thursday, shares of Disc Medicine traded near $70.37. The biotech company, which focuses on treatments for serious blood disorders, has a market cap of about $2.7 billion. Its forward P/E ratio is -9.33, reflecting its unprofitable status. The stock's 52-week range spans from $40 to $99.50, with a 50-day moving average of $68.55 and a 200-day moving average of $73.16. Disc Medicine has a current ratio of 24.00, indicating strong liquidity.

Analysts Set New Price Targets

Morgan Stanley maintained its 'buy' rating for Disc Medicine on June 16, 2026, with a price target of $85. Other firms like Wells Fargo and Stifel also upheld 'buy' ratings, with targets ranging from $79 to $110. The overall analyst consensus for Disc Medicine is a strong buy, with an average target price of $101.55 from 11 analysts.

About Disc Medicine

Disc Medicine, Inc., based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company. It develops treatments for serious blood-related diseases, focusing on red blood cell formation and function. Disc Medicine's pipeline includes several products, such as bitopertin and DISC-0974, targeting various types of anemia and other hematologic disorders. The company, led by CEO Dr. John D. Quisel, was founded in 2017 and employs 154 people.

Bottom Line

The insider sale by COO Yu Jonathan Yen-Wen is a notable event for Disc Medicine, a company deeply involved in innovative treatments for blood disorders. Investors and analysts closely follow such transactions, as they can provide insights into company leadership's outlook. However, it's important to remember that insider transactions don't always indicate future stock performance. Disc Medicine's activities and analyst ratings suggest ongoing interest in its potential within the biotech sector.